Disc Medicine, Inc. — Director's Dealing 2021

Mar 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gemini Therapeutics, Inc. /DE (GMTX)
CIK: 0001816736
Period of Report: 2021-03-01

Reporting Person: Strapps Walter (Chief Scientific Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.2846	2028-08-27	Common Stock (57668)		Direct
Stock Option (Right to Buy)	$2.5234	2030-03-10	Common Stock (11990)		Direct

Footnotes

F1: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, September 10, 2018 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

F2: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, March 10, 2020 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.